Brainsway Ltd Net Assets

Latest as of June 2026: ILA79.19 Million ILA ≈ $212.30K USD

Brainsway Ltd net assets. Based on the latest financial reports, Brainsway Ltd (BWAY) has net assets worth ILA79.19 Million ILA (≈ $212.30K USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA121.97 Million ≈ $327.01K USD) and total liabilities (ILA42.79 Million ≈ $114.71K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Brainsway Ltd growing its equity to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets ILA79.19 Million
% of Total Assets 64.92%
Annual Growth Rate 18.1%
5-Year Change 36.53%
10-Year Change 660.83%
Growth Volatility 84.26

Net Assets of Brainsway Ltd (2012–2025)

Net assets of Brainsway Ltd from 2012 to 2025. This chart illustrates how Brainsway Ltd's net assets have evolved over time, based on quarterly financial data. See BWAY equity financing ratio to measure how much of total assets are equity-financed.

Annual Net Assets for Brainsway Ltd (2012–2025)

The table below shows the annual net assets of Brainsway Ltd from 2012 to 2025. For live market cap and overall valuation, see BWAY market cap.

Year Net Assets Change
2025-12-31 ILA78.27 Million
≈ $209.83K
+25.60%
2024-12-31 ILA62.31 Million
≈ $167.06K
+49.86%
2023-12-31 ILA41.58 Million
≈ $111.48K
-8.41%
2022-12-31 ILA45.40 Million
≈ $121.71K
-20.81%
2021-12-31 ILA57.32 Million
≈ $153.68K
+191.96%
2020-12-31 ILA19.63 Million
≈ $52.64K
-18.93%
2019-12-31 ILA24.22 Million
≈ $64.93K
+248.39%
2018-12-31 ILA6.95 Million
≈ $18.64K
-45.35%
2017-12-31 ILA12.72 Million
≈ $34.10K
+23.66%
2016-12-31 ILA10.29 Million
≈ $27.58K
-20.22%
2015-12-31 ILA12.89 Million
≈ $34.57K
-17.22%
2014-12-31 ILA15.58 Million
≈ $41.76K
+6.32%
2013-12-31 ILA14.65 Million
≈ $39.28K
+62.65%
2012-12-31 ILA9.01 Million
≈ $24.15K
--

Equity Component Analysis

This analysis shows how different components contribute to Brainsway Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 6222089200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Brainsway Ltd Net Assets Breakdown (December 2025)

Brainsway Ltd net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Common Stock ILA430.09K 0.59%
Other Comprehensive Income ILA1.32 Million 1.80%
Other Components ILA162.25 Million 221.55%
Total Equity ILA73.24 Million 100.00%

Brainsway Ltd Competitors by Market Cap

The table below lists competitors of Brainsway Ltd ranked by their market capitalization.

Company Market Cap
Hung Ching Development & Construction Co Ltd
TW:2527
$394.61 Million
Sports Gear Co. Ltd
TW:6768
$394.64 Million
Vishnu Chemicals Limited
NSE:VISHNU
$394.68 Million
Ningxia Xiaoming Agriculture & Animal Husbandry Co.Ltd
SHE:300967
$394.70 Million
SAMPYO Cement Co. Ltd
KQ:038500
$394.32 Million
North American Financial 15
TO:FFN
$394.29 Million
Issta Lines Ltd
TA:ISTA
$394.29 Million
Eurocharm Holdings Co Ltd
TW:5288
$394.16 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Brainsway Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 62,313,000 to 73,236,200, a change of 10,923,200 (17.5%).
  • Net income of 8,262,499 contributed positively to equity growth.
  • Other comprehensive income increased equity by 3,506,273.
  • Other factors decreased equity by 845,572.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ILA8.26 Million +11.28%
Other Comprehensive Income ILA3.51 Million +4.79%
Other Changes ILA-845.57K -1.15%
Total Change ILA- 17.53%

Book Value vs Market Value Analysis

This analysis compares Brainsway Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2116.79x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 9090.31x to 2116.79x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-12-31 ILA0.40 ILA3656.00 x
2013-12-31 ILA0.61 ILA3656.00 x
2014-12-31 ILA1.09 ILA3656.00 x
2015-12-31 ILA0.89 ILA3656.00 x
2016-12-31 ILA0.71 ILA3656.00 x
2017-12-31 ILA0.86 ILA3656.00 x
2018-12-31 ILA0.42 ILA3656.00 x
2019-12-31 ILA1.18 ILA3656.00 x
2020-12-31 ILA0.88 ILA3656.00 x
2021-12-31 ILA1.84 ILA3656.00 x
2022-12-31 ILA1.48 ILA3656.00 x
2023-12-31 ILA1.25 ILA3656.00 x
2024-12-31 ILA1.79 ILA3656.00 x
2025-12-31 ILA1.73 ILA3656.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Brainsway Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 11.28%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 14.62%
  • • Asset Turnover: 0.50x
  • • Equity Multiplier: 1.54x
  • Recent ROE (11.28%) is above the historical average (-40.17%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 -120.88% -1624.27% 0.03x 2.18x ILA-6.41 Million
2013 -91.00% -598.99% 0.07x 2.28x ILA-7.90 Million
2014 -42.02% -193.64% 0.13x 1.65x ILA-8.10 Million
2015 -31.69% -60.10% 0.31x 1.72x ILA-5.38 Million
2016 -23.30% -20.80% 0.58x 1.94x ILA-3.43 Million
2017 -55.45% -63.29% 0.41x 2.12x ILA-8.33 Million
2018 -93.20% -39.51% 0.69x 3.39x ILA-7.17 Million
2019 -42.64% -44.71% 0.60x 1.60x ILA-12.75 Million
2020 -27.43% -24.41% 0.65x 1.73x ILA-7.35 Million
2021 -11.27% -21.79% 0.39x 1.32x ILA-12.19 Million
2022 -29.41% -49.12% 0.42x 1.42x ILA-17.89 Million
2023 -10.09% -13.20% 0.50x 1.51x ILA-8.36 Million
2024 4.69% 7.12% 0.43x 1.51x ILA-3.31 Million
2025 11.28% 14.62% 0.50x 1.54x ILA938.88K

Industry Comparison

This section compares Brainsway Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $21,251,000
  • Average return on equity (ROE) among peers: -47.45%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Brainsway Ltd (BWAY) ILA79.19 Million -120.88% 0.54x $394.54 Million
Allmed Solutions Ltd (ALMD) $53.96 Million -20.74% 0.07x $7.88 Million
Erika Carmel Ltd (BCUR) $15.04 Million -62.98% 1.31x $4.69 Million
Bio-View Ltd (BIOV) $27.61 Million 16.07% 0.40x $20.36 Million
Erech Finance Cahalacha Ltd (EFNC) $28.37 Million -88.27% 1.44x $816.18K
Epitomee Medical Ltd (EPIT) $33.95 Million -15.68% 0.18x $28.14 Million
Erika Carmel-Tech Ltd (ERKA) $8.97 Million 138.94% 4.32x $4.46 Million
Human Xtensions Ltd (HUMX) $15.51 Million -184.33% 0.31x $2.12 Million
Pulsenmore Ltd (PULS) $3.75 Million -126.31% 0.60x $22.89 Million
Sofwave Medical Ltd (SOFW) $4.12 Million -83.72% 0.51x $357.45 Million

About Brainsway Ltd

TA:BWAY Israel Medical Devices
Market Cap
$394.54 Million
ILA147.16 Billion ILA
Market Cap Rank
#13128 Global
#140 in Israel
Share Price
ILA3656.00
Change (1 day)
+3.72%
52-Week Range
ILA2423.00 - ILA5074.00
All Time High
ILA5074.00
About

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, … Read more